• Alcobra Ltd., of Tel Aviv, Israel, was issued U.S. Patent No. 8,476,304, related to modified-release Metadoxine. The formulation is used in the company's attention deficit hyperactivity disorder drug MG01CI.

• Cempra Inc., of Chapel Hill, N.C., was issued U.S Patent No. 8,450,300, "Fusidic Acid Dosing Regimens for Treatment of Bacterial Infections," covering the loading-dose regimen for Taskta. Taskta is an antibiotic candidate in a Phase II study in patients with prosthetic joint infections.

• Curis Inc., of Lexington, Mass., was issued U.S. Patent No. 8,461,157, related to new treatments for a number of cancers, using its PI3K-HDAC inhibitor CUDC-907.

• Fibrocell Science Inc., of Exton, Pa., was issued a U.S. patent for Laviv (azficel-T), related to azficel-T fibroblast suspension, which is a treatment for moderate to severe nasolabial fold wrinkles in adults.

• Genspera Inc., of San Antonio, was issued U.S. Patent No. 8,450,280, "Activation of Peptide Prodrugs by HK2." The patent is related to prodrugs activated by HK2 to deliver a thapsigargin derivative selectively to prostate cancers. HK2 is an active component of G-202, the company's lead drug candidate in Phase II trials for liver cancer after sorafenib therapy.

• Immunomedics Inc., of Morris Plains, N.J., was issued U.S. Patent No. 8,444,956 for methods of labeling peptides and other molecules, such as antibodies, with fluorine-18 (F-18) and fluorine-19 (F-19). Those radionuclides can be used to positron-emission tomography (F-18) and magnetic resonance imaging (F-19).

• Intellicell Biosciences Inc., of New York, was issued U.S. Patent No. 8,440,440, for patent stem cell extraction technology. The technology separates stromal vascular fraction cells from adipose tissue and does not use enzymes.

• Kempharm Inc., of North Liberty, Iowa, was issued U.S. Patent No. 8,461,137, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof." The patent covers KP201, benzhydrocodone, its prodrug of hydrocodone.

• Lpath Inc., of San Diego, was issued U.S. Patent No. 8,444,970, "Compositions and Methods for the Treatment and Prevention of Ocular Conditions." The patent covers methods of using monoclonal antibodies, such as Isonep, for treating ocular conditions including wet age-related macular degeneration.

• Momenta Pharmaceuticals Inc., of Cambridge, Mass., said Rockefeller University was issued U.S. Patent No. 8,470,318, "Polypeptides With Enhanced Anti-inflammatory and Decreased Cytotoxic Properties and Related Methods." Momenta is the exclusive license holder of that patent.